Viatris

Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…

FY22 revenue at Rs 8,397 crores, up 14 per cent; core EBITDA up 18 per cent at Rs 2,669 crores; PBT (before Exceptional Item) at…

Great Place to Work is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees…

Viatris to provide commercial and other transition services for an expected period of two years to ensure continuity of customer…

Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee

Branded and unbranded versions of the first-ever interchangeable biosimilar in the US provide more affordable options for the…

Express Scripts, a leading pharmacy benefit management organisation, will list Viatris-labelled biosimilar Insulin Glargine as a…

While patients will be increasingly prescribed Viatris/Biocon’s Semglee over Sanofi’s Lantus due to its competitive pricing,…

Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s…

Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth